Our commitment to patients is uncompromising
Patients come first at Vertex
We are relentless in our pursuit to create transformative medicines for people with serious and life-threatening diseases. This has been our singular purpose for more than 30 years.
Our core values drive our patient-centric mentality. Our Uncompromising Commitment to Patients value is why we understand the importance of going beyond research and development to engage in advocacy, awareness and community support. It’s why we are committed to engaging with patient organisations around the globe — to ensure our work is always centred on addressing the lived experiences of people with serious diseases, carers and families.
And we wouldn’t be where we are today without the incredible patient communities – thank you.
The Vertex patient commitment
Patients are at the heart of everything we do
Vertex is committed to its mission of developing transformative medicines for people with serious diseases. We seek to identify opportunities where we can partner with and learn from patients living with rare diseases, like cystic fibrosis (CF), and represent the community voice within Vertex.
We strive to:
-
Put patients first and at the centre of everything we do
-
Communicate in a way that is accurate, honest, transparent and clear
-
Listen with empathy and learn from patients and carers
-
Respect the relationship between patients and their doctors
-
Empower patients by helping them to access the information and resources they need to manage their disease
-
Support initiatives that help patients to live fuller, more engaged lives
-
Encourage and provide opportunities for our employees to engage in the community
Working with Patient Groups in Australia
In Australia, Vertex adheres to the key principles and advice outlined in the Working Together Guide. This resource has been designed to help health consumer organisations (HCOs), also known as patient advocacy groups (PAGs), and research-based pharmaceutical companies, to responsibly and successfully collaborate with each other, with the goal of improving health outcomes and quality of life for Australians.
Developed by the Consumers Health Forum (CHF) and Medicines Australia (MA), the guide reinforces the value of strong relationships between HCOs/PAGs and pharmaceutical companies, based on the principles of independence, trust, fairness, openness, transparency, confidentiality and accountability.
These collaborations can help to raise awareness of health conditions and related issues, and lead to the development of information and educational resources. Most importantly, they can help companies like Vertex to better understand the needs of patients and their carers.
The MA Code of Conduct is the national benchmark for accountability and transparency reporting in the local medicines industry. Although Vertex is currently not a member of MA, we follow the spirit of the code and are committed to maintaining the highest ethical standards in everything we do. We believe it’s important to align with the rest of the Australian innovative prescriptions medicines industry, in supporting greater transparency and visibility of the relationships between the pharmaceutical companies and healthcare stakeholders. HCO Support Reports for each calendar year must be provided to MA by 30 April of the following year. Reports will be published online on 30 June each year, for the previous calendar year.
